Novacyt Enlists MDL Asia To Step Up APAC Liquid Cytology Sales
This article was originally published in Clinica
Executive Summary
Cervical cancer screening specialist Novacyt is intensifying its international commercial focus by enlisting MDL Asia to take charge of product distribution across Asia-Pacific, excluding Greater China.
You may also be interested in...
Novacyt Full Of Eastern Promise, Following Strong H1 Sales
Cervical cancer screening firm Novacyt is aiming to broaden its market penetration in Asia-Pacific by identifying strategic acquisitions. The Anglo-French firm posted strong sales growth of 40% for the first six months of 2017, with APAC representing the group's fastest growing region.
Small-Cap Recap: Fiscal 2016 Spells Sea Change For Angle; Cellnovo; Novacyt; Nanobiotix
A status update on four startups working in the molecular diagnostics and radiotherapy sectors.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.